Table: Sapporo Clinical Lab -2023/24 group results

Sapporo Clinical Laboratory

13/05/2024 07:30

May 13 (Reuters)- 
          Sapporo Clinical Laboratory Co Ltd 
          CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)
                 Year ended      Year ended       Year to       NEXT   
              Mar 31, 2024    Mar 31, 2023   Mar 31, 2025     YEAR     
                 LATEST         YEAR-AGO        COMPANY      COMPANY   
                 RESULTS         RESULTS       FORECAST    H1 FORECAST 
  Sales           19.68           20.13          19.80         9.80    
               (-2.2 pct)      (+5.3 pct)     (+0.6 pct)    (-0.6 pct) 
  Operating      534 mln           1.01         500 mln      221 mln   
               (-47.0 pct)     (-34.4 pct)    (-6.4 pct)   (-24.1 pct) 
  Recurring      514 mln           1.16         493 mln      226 mln   
               (-55.6 pct)     (-27.8 pct)    (-4.2 pct)   (-23.4 pct) 
  Net
  Net            380 mln         568 mln        320 mln      141 mln   
               (-33.1 pct)     (-45.5 pct)    (-15.8 pct)  (-37.6 pct) 
  EPS          114.14 yen      170.53 yen     102.36 yen    45.13 yen  
  Ann Div       23.00 yen       23.00 yen      23.00 yen               
  -Q2 Div          NIL             NIL            NIL                  
  -Q4 Div       23.00 yen       23.00 yen      23.00 yen               
  
  NOTE - Sapporo Clinical Laboratory Co Ltd.
  *Second Net profit row denotes profit attributable to owners ofthe parent 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=9776.T